BEGIN:VCALENDAR
VERSION:2.0
PRODID:Linklings LLC
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
X-LIC-LOCATION:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:19700308T020000
RRULE:FREQ=YEARLY;BYMONTH=3;BYDAY=2SU
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:19701101T020000
RRULE:FREQ=YEARLY;BYMONTH=11;BYDAY=1SU
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTAMP:20241017T183511Z
LOCATION:Harbor Ballrooms D-I
DTSTART;TZID=America/Los_Angeles:20241016T112000
DTEND;TZID=America/Los_Angeles:20241016T114000
UID:ncs_NCS 2024_sess125_ccrnt160@linklings.com
SUMMARY:Innovative Approach for Prognostication in Traumatic Brain Injury 
 - Biomarkers & Endophenotypes
DESCRIPTION:Breakout Session\n\nPatrick Chen (University of California, Ir
 vine)\n\nSignificant scientific progress in the past two decades has deepe
 ned our comprehension of the intricate and diverse pathophysiological mech
 anisms linked with traumatic brain injury (TBI). Concurrently, numerous ex
 perimental therapeutics have exhibited neuroprotective properties in precl
 inical studies. Regrettably, none of these approaches have demonstrated ef
 ficacy in clinical trials for TBI. The failure of clinical therapy trials 
 is often attributed to TBI's heterogeneity, the oversimplified TBI classif
 ications, the lack of biomarkers for therapeutic intervention monitoring, 
 and the limited translatability of preclinical TBI models.\n\nRecognized n
 ow is the multifaceted nature of TBI pathophysiology, which involves acute
 , progressive, and chronic neurodegenerative processes, comprising intrica
 te cascades of biological events at cellular and molecular levels. Corresp
 onding to the diverse pathophysiologic processes in TBI, a range of TBI bi
 ofluid-based protein biomarkers and endophenotypes have been identified. T
 hese biomarkers encompass axonal injury, dendritic injury, neuronal injury
 , demyelination, synaptic injury, astroglia injury, and microglia response
 s. Other plausible links between TBI and long-term outcomes include a comb
 ination of: alterations in neurobiological mechanisms and the emergence of
  other medical comorbidities after injury; and subsequent behavioral and l
 ifestyle changes that put patients at higher risk of poor outcomes. \n\nTh
 is talk will provide an update on the current understanding of TBI bioflui
 d-based protein biomarkers, and other emerging post-TBI long-term medical 
 comorbidities and endophenotypes. It will also delve into biomarker eviden
 ce in TBI diagnosis, outcome prognosis, and their role as theranostics too
 ls.\n\nTrack: Science of Neurocritical Care\n\nFocus Area: Informatics, Nu
 rsing Pharmacology, Traumatic Brain Injury\n\nTarget Audience: Advanced\n\
 nSession Chair: Molly McNett (The Ohio State University)
END:VEVENT
END:VCALENDAR